Rockwell Medical (RMTI)
Manufactures hemodialysis concentrates and develops adjacent renal-care products.
Something off on this page? Send us feedback.
Manufactures and distributes hemodialysis concentrates for dialysis clinics and adds renal-care products that fit its infrastructure. Following the Evoqua acquisition and the discontinuation of U.S. Triferic sales, its strategy centers on a profitable concentrates business.
Manufactures and distributes hemodialysis concentrates for dialysis clinics, with liquid and powder bicarbonate, liquid-acid concentrates, and single-use bicarbonate cartridges in the portfolio. The product range serves dialysis providers. Its concentrates business was broadened through the Evoqua acquisition, whose assets included contracts, intellectual property, and FDA 510(k) clearances.
Developed and commercialized the ferric-pyrophosphate-citrate Triferic platform before discontinuing U.S. sales. The strategy now centers on a profitable concentrates business and renal-care products that fit its infrastructure. Operations depend on manufacturing and transportation execution, while cash needs also depend on revenue forecasts and those costs.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 9, 2026 | H.C. Wainwright | Reiterate | Buy | $2 | $20 |
| May 22, 2026 | H.C. Wainwright | Target | $3 | $2 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $24.8M · Total debt $13.9M · Total assets $56.5M · Shareholders' equity $35.1M
- Revenue
- $17.8M
- Operating income
- −$1.1M
- Net income
- −$1.2M
No dividends on record.
| Institutions44 holders · as of Mar 31, 2026 | 10.08% | 397.8K shares | |
| Insiders12 holders · as of Jul 6, 2026 | 7.85% | 309.8K shares | |
| Strategic holders1 holder · as of Apr 15, 2025 | 9.03% | 356.5K shares | |
| Otherremainder | 73.04% | 2.88M shares |
3.95M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Irrevocable Larson Family Investment TrustStrategic10 percent owner | 9.03% | 356,500 | Form 4filed Apr 15, 2025 ↗ |
Vanguard Capital Management LLCInstitution | 3.00% | 1.18M | 13Fas of Mar 31, 2026 |
Renaissance Technologies LLCInstitution | 1.62% | 639,120 | 13Fas of Mar 31, 2026 |
Mark StrobeckInsiderdirector, officer: President and CEO | 1.58% | 62,349 | Form 4filed Jul 6, 2026 ↗ |
Geode Capital Management, LLCInstitution | 1.09% | 429,180 | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jan 2, 2026 | Jesse Neri | officer: SVP and CFO | −886 | $0.8355 |
| Jan 2, 2026 | Heather Hunter | officer: Chief Operating Officer | −2,868 | $0.8355 |
| Nov 18, 2025 | John G. Cooper | director | −5,079 | $0.8700 |
| Oct 1, 2025 | Heather Hunter | officer: SVP, Chief Operating Officer | −2,868 | $1.19 |
| Oct 1, 2025 | Mark Strobeck | director, officer: President and CEO | −6,926 | $1.19 |
- Fresenius Medical Care (ADR)
Integrated renal supplier with hemodialysis concentrates
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Rockwell Medical | $8.07 | +0.31% | $31.9M | — | — | 0.5 | +10.6% |
| Fresenius Medical Care (ADR) | $22.55 | −0.49% | $12.17B | 11.7 | 16.4 | 0.5 | −0.7% |
| Median | 11.7 | 16.4 | 0.5 | −0.7% |